Last 47 quarters of trend data · Healthcare · Medical - Healthcare Plans
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Cigna Corporation's quarterly P/E stands at 10.3x, down 68.6% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 16.6% YoY to 8.0x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 23.91 | 10.34 | 14.47 | 16.96 | 13.46 | 32.93 | 15.16 | — | 21.45 | 15.09 | 14.26 | 15.07 | 21.63 |
| — | -68.6% | -4.6% | — | -37.3% | +118.3% | +6.4% | — | -0.8% | +95.1% | +5.8% | -6.2% | +27.3% | |
| P/S Ratio | 0.31 | 0.28 | 0.33 | 0.36 | 0.29 | 0.38 | 0.39 | 0.45 | 0.43 | 0.43 | 0.43 | 0.41 | 0.55 |
| — | -27.6% | -15.0% | -21.7% | -32.3% | -11.7% | -9.5% | +10.6% | -22.0% | -8.0% | -6.1% | -6.1% | +33.5% | |
| P/B Ratio | 1.99 | 1.84 | 2.19 | 2.31 | 1.86 | 2.30 | 2.26 | 2.52 | 1.90 | 1.86 | 1.83 | 1.71 | 2.25 |
| — | -20.2% | -3.0% | -8.4% | -2.3% | +24.1% | +23.6% | +46.9% | -15.5% | -1.8% | +1.3% | +2.7% | +40.3% | |
| P/FCF | 8.52 | 6.15 | — | 14.62 | 3.93 | — | — | 5.73 | 20.01 | 8.77 | 9.94 | 4.13 | 14.42 |
| — | — | — | +155.2% | -80.3% | — | — | +38.6% | +38.7% | +21.1% | -55.9% | -62.6% | +202.7% | |
| EV / EBITDA | 9.02 | 8.04 | 9.24 | 10.90 | 8.97 | 9.64 | 9.44 | 10.71 | 9.85 | 8.95 | 8.94 | 9.14 | 12.76 |
| — | -16.6% | -2.2% | +1.8% | -9.0% | +7.7% | +5.6% | +17.2% | -22.8% | -6.9% | -0.5% | -0.1% | +11.0% | |
| EV / EBIT | 10.70 | 9.97 | 12.20 | 12.09 | 11.02 | 11.76 | 12.05 | 14.00 | 11.73 | 11.02 | 12.01 | 12.61 | 18.05 |
| — | -15.3% | +1.2% | -13.7% | -6.1% | +6.8% | +0.4% | +11.0% | -35.0% | -14.2% | +1.8% | +5.5% | +23.3% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Cigna Corporation's operating margin was 3.7% in Q3 2025, up 0.1 pp QoQ and down 0.3 pp YoY. Gross margin contracted 17.8% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 10.5% | 8.5% | 11.7% | 10.1% | 9.8% | 10.4% | 10.8% | 11.2% | 12.9% | 13.2% | 12.6% | 12.9% | 12.4% |
| — | -17.8% | +9.0% | -9.6% | -23.5% | -21.6% | -14.4% | -13.7% | +3.4% | +4.0% | -6.8% | -3.9% | -0.3% | |
| Operating Margin | 3.8% | 3.7% | 3.6% | 3.0% | 3.3% | 4.0% | 4.0% | 3.9% | 4.0% | 4.6% | 4.6% | 4.3% | 3.8% |
| — | -8.6% | -9.2% | -23.6% | -17.9% | -11.4% | -12.8% | -9.0% | +5.4% | -3.5% | -12.3% | -12.9% | +13.6% | |
| Net Margin | 1.4% | 2.7% | 2.3% | 2.0% | 2.2% | 1.2% | 2.6% | -0.5% | 2.0% | 2.9% | 3.0% | 2.7% | 2.6% |
| — | +130.8% | -10.9% | +517.5% | +7.7% | -59.6% | -14.9% | -117.8% | -22.8% | -52.9% | -12.2% | +0.1% | +6.7% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 7.8% | 4.5% | 3.8% | 3.2% | 3.4% | 1.8% | 3.7% | -0.6% | 2.2% | 3.1% | 3.2% | 2.8% | 2.6% |
| — | +157.0% | +1.5% | +613.0% | +52.6% | -42.8% | +15.3% | -122.3% | -15.6% | -49.0% | -4.1% | +10.3% | +12.3% | |
| ROA | 2.2% | 1.2% | 1.0% | 0.9% | 0.9% | 0.5% | 1.0% | -0.2% | 0.7% | 0.9% | 1.0% | 0.9% | 0.8% |
| — | +155.6% | +1.0% | +576.6% | +33.5% | -49.8% | +2.4% | -120.9% | -17.8% | -49.4% | -4.0% | +11.5% | +14.7% | |
| ROIC | 10.5% | 2.8% | 2.8% | 2.3% | 2.4% | 2.8% | 2.7% | 2.5% | 2.2% | 2.5% | 2.4% | 2.2% | 1.9% |
| — | -0.7% | +3.1% | -7.9% | +7.8% | +16.0% | +13.2% | +15.8% | +20.2% | +11.1% | +2.6% | +0.0% | +25.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Cigna Corporation's Debt/EBITDA ratio is 10.4x, up from 9.9x last quarter — elevated, raising questions about debt serviceability. Debt/Equity has risen for 3 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.78 | 0.81 | 0.76 | 0.75 | 0.78 | 0.78 | 0.77 | 0.79 | 0.67 | 0.68 | 0.72 | 0.73 | 0.70 |
| — | +4.5% | -0.9% | -4.9% | +16.2% | +14.0% | +6.8% | +8.6% | -4.9% | -4.3% | -2.6% | -0.2% | -3.3% | |
| Debt / EBITDA | 2.86 | 10.39 | 9.88 | 11.51 | 11.34 | 10.17 | 10.12 | 10.93 | 10.95 | 10.36 | 11.00 | 11.77 | 12.70 |
| — | +2.2% | -2.4% | +5.3% | +3.6% | -1.8% | -8.0% | -7.1% | -13.8% | -7.4% | +1.5% | +1.3% | -15.5% | |
| Current Ratio | 0.84 | 0.83 | 0.79 | 0.78 | 0.84 | 0.86 | 0.83 | 0.83 | 0.77 | 0.73 | 0.73 | 0.72 | 0.73 |
| — | -4.0% | -5.6% | -6.3% | +9.9% | +17.6% | +13.8% | +16.5% | +4.9% | -0.0% | -11.4% | -11.7% | -11.9% | |
| Quick Ratio | 0.73 | 0.73 | 0.68 | 0.69 | 0.73 | 0.77 | 0.74 | 0.75 | 0.65 | 0.64 | 0.64 | 0.62 | 0.61 |
| — | -5.9% | -7.9% | -7.6% | +11.8% | +20.9% | +16.2% | +19.8% | +5.9% | +0.6% | -14.3% | -14.9% | -17.4% | |
| Interest Coverage | 6.56 | 7.43 | 7.22 | 5.44 | 6.00 | 6.85 | 6.43 | 7.01 | 5.72 | 6.14 | 6.12 | 5.63 | 5.40 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonCigna Corporation's current P/E is 23.9x. The average P/E over the last 4 quarters is 13.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Cigna Corporation's current operating margin is 3.8%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Cigna Corporation's business trajectory between earnings reports.